OS Therapies (OSTX) said Wednesday it closed the acquisition of listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals.
The biopharmaceutical company said it has acquired clinical, preclinical, and intellectual property assets, including immunotherapy programs for human papilloma virus-associated cancers, non-small cell lung cancer, and prostate cancer.
OS Therapies said it is targeting the approval of its OST-HER2 immunotherapy candidate for fully resected, lung metastatic osteosarcoma by the end of 2025.
It also said that new manufacturing-based intellectual property protects the listeria-based immunotherapy platform and cancer immunotherapy candidates through 2040.
Price: 1.25, Change: -0.06, Percent Change: -4.58
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。